LOGO
LOGO

Corporate News

Hensoldt Q1 Adj. EBITDA Down; Confirms FY25 Guidance

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Hensoldt AG (HAGHY), a German defense and security electronics company, reported that its adjusted EBITDA for the first quarter 2025 declined to 30 million euros from the previous year's 33 million euros.

Order intake was 701 million euros in the first quarter, compared to 665 million euros in the previous year.

Revenues for the quarter to 395 million euros, an increase from last year's 329 million euros. Alongside additional revenue from the ESG Group's business activities, this was mainly due to strong revenue growth in the Optronics segment.

The company said it now has the technologies, solutions and operational capabilities to play a significant role in the upcoming German and EU procurement programs and to increase its previous ambition of 5 billion euros in revenue by 2030 to up to 6 billion euros.

The company confirmed its guidance for the financial year 2025. The company anticipates revenue of 2.50 billion euros to 2.60 billion euros and a book-to-bill ratio of around 1.2x. Profitability will be reported as an adjusted EBITDA margin and is expected to be around 18%. Continued German and European investment in security and defense will result in further high demand for the company's products and solutions.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

RELATED NEWS
Latest Updates on COVID-19